Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A versus pembrolizumab first-line study in PD-L1-positive metastatic non-small cell lung cancer
jRCT2021210025Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of vibostolimab and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Aug 2021; status: completed.
02
Drugs
vibostolimabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021210025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210025.